GSK: Not interested in Gemzyme deal

Despite rumors, GlaxoSmithKline's Patrick Vallance, senior vice president of medicines discovery and development, says his company isn't considering a bid for Genzyme. He fears a major buyout would disrupt GSK's current research. "Those kind of big deals are incredibly destructive to research and development," Vallance told reporters in Massachusetts, as reported by Reuters. "There is an argument for maintaining a stable R&D organization."

GSK is more interested in small deals, like purchasing options to develop a biotech's drug. That allows the Pharma giant to take potential products for a "test drive" before investing heavily in the company or technology. Vallance also reiterated GSK's plan to focus on rare diseases where there's less competition and pricing pressure, instead of broad indications like depression and schizophrenia. Vallance's comments were made a the headquarters of Sirtris, a longevity-research company GSK purchased in 2008 for $720 million. Results from Sirtris' clinical trials of its lead drug SRT2104 are due next year.

- take a look at the Reuters write-up

Suggested Articles

The platform, which is in use at companies including Agios, enables researchers to simultaneously detect DNA and protein changes in single cells. 

As Urovant gears up for the launch of vibegron, its overactive bladder treatment, it is pushing the same drug through the clinic in other indications.

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.